Table 1.

Lesion and treatments in the different experimental groups

Group codesnHCbDrug treatment
CTRL-Eth16Ethanol (400 μl, 0.5% saline, i.p., for 7 d)
HCb-Eth16XEthanol (400 μl, 0.5% saline, i.p., for 7 d)
CTRL-ACEA5ACEA (5 mg/kg, i.p., for 7 d)
HCb-ACEA5XACEA (5 mg/kg, i.p., for 7 d)
CTRL-SR15SR141716A (3 mg/kg, i.p., for 7 d)
HCb-SR15XSR141716A (3 mg/kg, i.p., for 7 d)
CTRL-JWH16JWH-015 (3 mg/kg, i.p., for 7 d)
HCb-JWH16XJWH-015 (3 mg/kg, i.p., for 7 d)
CTRL-SR216SR144528 (3 mg/kg, i.p., for 7 d)
HCb-SR216XSR144528 (3 mg/kg, i.p., for 7 d)
CTRL-CAPS5Capsaicin (1 mg/kg, i.p., for 7 d)
HCb-CAPS5XCapsaicin (1 mg/kg, i.p., for 7 d)
CTRL-CAPZ5Capsazepine (3 mg/kg, i.p., for 7 d)
HCb-CAPZ5XCapsazepine (3 mg/kg, i.p., for 7 d)
CTRL-LY-Eth5LY294002 (15 μg/10 μl; 25% DMSO, i.c.v.) + ethanol (400 μl, 0.5% saline, i.p., for 7 d)
HCb-LY-Eth5XLY294002 (15 μg/10 μl; 25% DMSO i.c.v.) + ethanol (400 μl, 0.5% saline, i.p., for 7 d)
CTRL-LY-JWH5LY294002 (15 μg/10 μl; 25% DMSO i.c.v.) + JWH-015 (3 mg/kg, i.p., for 7 d)
HCb-LY-JWH5XLY294002 (15 μg/10 μl; 25% DMSO i.c.v.) + JWH-015 (3 mg/kg, i.p., for 7 d)
CTRL-SP-Eth5SP600125 (30 μg/10 μl; 25% DMSO i.c.v.) + ethanol (400 μl, 0.5% saline, i.p., for 7 d)
HCb-SP-Eth5XSP600125 (30 μg/10 μl; 25% DMSO i.c.v.) + ethanol (400 μl, 0.5% saline, i.p., for 7 d)
CTRL-SP-JWH5SP600125 (30 μg/10 μl; 25% DMSO i.c.v.) + JWH-015 (3 mg/kg, i.p., for 7 d)
HCb-SP-JWH5XSP600125 (30 μg/10 μl; 25% DMSO i.c.v.) + JWH-015 (3 mg/kg, i.p., for 7 d)
  • CTRL, Control.